Christina Swärd

Summary

Affiliation: Sahlgrenska University Hospital
Country: Sweden

Publications

  1. doi request reprint [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney
    Christina Swärd
    Department of Surgery, University of Gothenburg, Sahlgrenska University Hospital, 413 45, Goteborg, Sweden
    World J Surg 34:1368-72. 2010
  2. doi request reprint Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1
    Christina Swärd
    The Lundberg Laboratory for Cancer Research, Sahlgrenska University Hospital, Goteborg, Sweden
    Cancer Biother Radiopharm 23:114-20. 2008
  3. ncbi request reprint A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis
    Viktor Johanson
    Lundberg Laboratory for Cancer Research, Sahlgrenska University Hospital, SE 413 45 Goteborg, Sweden
    Endocr Relat Cancer 14:433-44. 2007
  4. ncbi request reprint Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice
    Viktor Johanson
    The Lundberg Laboratory for Cancer Research, Sahlgrenska University Hospital, Goteborg, Sweden
    Neuroendocrinology 82:171-6. 2005
  5. ncbi request reprint Chromogranin A as a determinant of midgut carcinoid tumour volume
    Lars Kölby
    The Lundberg Laboratory for Cancer Research, Sahlgrenska University Hospital, SE 413 45 Goteborg, Sweden
    Regul Pept 120:269-73. 2004
  6. doi request reprint High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids
    Ellinor Andersson
    Lundberg Laboratory for Cancer Research, Department of Pathology, Sahlgrenska University Hospital, Gula straket 8, SE 413 45 Goteborg, Sweden
    Endocr Relat Cancer 16:953-66. 2009

Collaborators

Detail Information

Publications6

  1. doi request reprint [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney
    Christina Swärd
    Department of Surgery, University of Gothenburg, Sahlgrenska University Hospital, 413 45, Goteborg, Sweden
    World J Surg 34:1368-72. 2010
    ..Peptide receptor radiation therapy (PRRT) using [(177)Lu-DOTA(0)-Tyr(3)]-octreotate is a new, promising option for treatment of disseminated gastroenteropancreatic neuroendocrine tumors (GEPNETs)...
  2. doi request reprint Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1
    Christina Swärd
    The Lundberg Laboratory for Cancer Research, Sahlgrenska University Hospital, Goteborg, Sweden
    Cancer Biother Radiopharm 23:114-20. 2008
    ..Octreotate seems to be a more suitable somatostatin analog than octreotide for receptor-mediated radiation therapy. P-CgA is a simple, accurate method for the estimation of tumor response in this animal model...
  3. ncbi request reprint A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis
    Viktor Johanson
    Lundberg Laboratory for Cancer Research, Sahlgrenska University Hospital, SE 413 45 Goteborg, Sweden
    Endocr Relat Cancer 14:433-44. 2007
    ..Our results show that this transplantable MTC, designated GOT2, represents a novel and useful model for studies of MTC and RET tyrosine kinase-dependent tumor growth...
  4. ncbi request reprint Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice
    Viktor Johanson
    The Lundberg Laboratory for Cancer Research, Sahlgrenska University Hospital, Goteborg, Sweden
    Neuroendocrinology 82:171-6. 2005
    ..Our results indicate that CHS 828 can be a candidate drug for treatment of neuroendocrine tumours...
  5. ncbi request reprint Chromogranin A as a determinant of midgut carcinoid tumour volume
    Lars Kölby
    The Lundberg Laboratory for Cancer Research, Sahlgrenska University Hospital, SE 413 45 Goteborg, Sweden
    Regul Pept 120:269-73. 2004
    ..037). In conclusion, this study demonstrates that plasma CgA levels are closely correlated to tumour burden, and that plasma CgA is well suited for monitoring the clinical course and outcome of treatment in patients with NE tumours...
  6. doi request reprint High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids
    Ellinor Andersson
    Lundberg Laboratory for Cancer Research, Department of Pathology, Sahlgrenska University Hospital, Gula straket 8, SE 413 45 Goteborg, Sweden
    Endocr Relat Cancer 16:953-66. 2009
    ..Predictive fluorescence in situ hybridization analysis of chromosome 14 status in patients with ileal carcinoids is suggested...